In the evolving landscape of anesthetic management for elderly patients, the impact of anesthetic agents on cognitive outcomes remains a critical area of investigation. Recent research published in BMC Geriatrics in 2026 has provided new insights into the differential effects of desflurane and propofol on perioperative neurocognitive disorders (PND) in older adults undergoing major urological surgeries. This randomized, controlled trial extends our understanding of how anesthetic choices may influence postoperative cognitive trajectories, a subject of immense importance given the increasing aging population and prevalence of complex surgeries in this demographic.
Perioperative neurocognitive disorders encompass a spectrum of cognitive impairments that arise in the perioperative period, including delirium and longer-lasting cognitive decline. Older adults are particularly susceptible due to age-related neurodegenerative changes, comorbidities, and the physiological stresses induced by anesthesia and surgery. Establishing whether specific anesthetics can exacerbate or mitigate these neurocognitive phenomena has significant implications for optimizing perioperative care and improving long-term functional outcomes for elderly patients.
The study under discussion rigorously compared desflurane, a volatile inhaled anesthetic known for its rapid onset and recovery, with propofol, an intravenous sedative-hypnotic agent valued for its favorable safety profile and neuroprotective properties observed in preclinical studies. The trial enrolled a robust cohort of older individuals scheduled for extensive urological procedures, randomizing them to receive either desflurane or propofol-based anesthesia. Cognitive function was meticulously assessed preoperatively and at multiple postoperative intervals using standardized neuropsychological tests sensitive to subtle cognitive changes, allowing for detailed temporal mapping of cognitive trajectories.
Findings from this investigation demonstrated notable differences between the two anesthetic regimens regarding the incidence and severity of perioperative neurocognitive disorders. Patients anesthetized with desflurane exhibited a higher frequency of early postoperative delirium and more pronounced cognitive decline at follow-ups compared to those who received propofol. These results resonate with emerging evidence suggesting that volatile anesthetics may contribute to neuroinflammation and neuronal stress, mechanisms hypothesized to underlie PND, whereas propofol’s antioxidative and anti-inflammatory effects potentially confer neuroprotection.
Critically, the study employed strict methodological standards to minimize bias and confounding, including blinding of outcome assessors and adjustment for variables such as baseline cognitive status, comorbidity burden, and surgical complexity. This rigorous approach increases confidence that the observed differences in cognitive outcomes stem from the anesthetic agents themselves rather than extraneous factors. Furthermore, the trial’s focus on major urological surgeries — procedures that are often lengthy and physiologically demanding — adds clinical relevance, as these patients typically face heightened risks of adverse neurocognitive sequelae.
The implications of these findings extend beyond a mere comparison of anesthetic efficacy and safety. They invite a reevaluation of perioperative protocols for elderly patients, advocating for anesthetic strategies that prioritize cognitive preservation alongside hemodynamic stability and analgesia. Propofol’s apparent advantage in attenuating PND risk may encourage clinicians to tailor anesthesia plans more judiciously, potentially integrating adjunctive measures such as enhanced monitoring of cerebral oxygenation and inflammation markers.
Mechanistically, the differential impact of desflurane and propofol on cognitive outcomes may relate to their interactions with neuronal glutamate receptors, modulation of synaptic plasticity, and influence on the blood-brain barrier permeability. Desflurane, despite its rapid elimination, has been associated with increased production of reactive oxygen species and microglial activation in animal models, processes that can trigger neuroinflammation and synaptic dysfunction. In contrast, propofol’s chemical structure facilitates scavenging of free radicals and suppression of pro-inflammatory cytokines, suggesting a neuroprotective milieu during the vulnerable perioperative period.
Additionally, this study sheds light on the critical period immediately after surgery, where interventions targeting delirium prevention could be best leveraged. The higher delirium rates observed with desflurane highlight the necessity for vigilant postoperative cognitive assessments and early rehabilitative efforts in patients exposed to volatile anesthetics. Conversely, the more favorable cognitive profile seen with propofol might translate into shorter hospital stays, reduced postoperative complications, and better quality of life trajectories, outcomes that remain to be explored in subsequent longitudinal research.
Beyond the direct effects on cognition, the choice of anesthetic also influences systemic physiological responses including hemodynamic fluctuations and respiratory function, which can indirectly affect brain perfusion and oxygenation. This study’s comprehensive monitoring protocols provide a nuanced framework for balancing these considerations while still focusing on optimizing neurological outcomes in frail and complex surgical populations.
The authors acknowledge certain limitations such as the single-center design and the need for larger-scale multicenter studies to validate these results across diverse patient populations and surgical contexts. Nonetheless, this investigation constitutes a significant advancement in the personalized management of anesthesia in elderly patients, framing future research priorities that integrate neurocognitive outcomes as central endpoints in anesthesiology trials.
In conclusion, this landmark trial delineates a clear divergence in neurocognitive outcomes based on the anesthetic agent used, favoring propofol over desflurane in terms of mitigating perioperative neurocognitive disorders in older adults undergoing major urological surgery. These insights compel a paradigm shift towards individualized anesthetic regimens that prioritize cognitive health, thereby enhancing recovery trajectories and long-term well-being in the vulnerable aging population. As the global burden of neurocognitive disorders grows, such targeted perioperative strategies stand poised to transform clinical practice and elevate standards of geriatric surgical care profoundly.
Subject of Research: Effects of anesthetic agents on perioperative neurocognitive disorders in elderly patients undergoing major urological surgery.
Article Title: Effect of desflurane versus propofol on perioperative neurocognitive disorders in older adults undergoing major urological surgery: a randomized trial.
Article References:
Somnuke, P., Siriussawakul, A., Pongraweewan, O. et al. Effect of desflurane versus propofol on perioperative neurocognitive disorders in older adults undergoing major urological surgery: a randomized trial. BMC Geriatr (2026). https://doi.org/10.1186/s12877-026-07823-x
Image Credits: AI Generated
